Reducing drug-related readmissions in older patients with pharmacist support

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of a clinical pharmacist intervention aimed at reducing drug-related readmissions among patients over 75 years old. The study involves a randomized controlled design where participants receive enhanced pharmacist services, including regular medication reviews and follow-up calls to discuss adherence and potential drug-related issues. Data on patient adherence and quality of life will be collected at baseline and during follow-up periods of 30 and 180 days. The intervention focuses on improving the transition of care from hospital to primary care settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Living at home
* Acutely admitted
* Registered at one of ten pre-specified primary care health centers

Exclusion Criteria:

* Patients unable to communicate or who do not speak Swedish
* Patients scheduled for palliative care
* Patients admitted due to intoxication by alcohol or drug (non prescription)

Where it's running

• Medical Centre, University Hospital of Umeå
  Umeå, Sweden Recruiting

Study contacts

• Principal investigator: Maria Gustafsson, Ph.D — Umeå University
• Study coordinator: Kindstedt
• Email: jonas.kindstedt@umu.se
• Phone: +46706572422

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Project REACH: Telehealth at syringe service programs to help people who use drugs access HIV-related care

  A telehealth program at syringe service sites will try to connect adults who use drugs with HIV-related services to see if it is feasible and acceptable and may help them get care.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07433712

• Online program to support families of LGBTQ youth

  This study is testing an online program to help families of LGBTQ youth understand and support their children better, especially those from diverse backgrounds.

  Recruiting Phase 2 University of Michigan · Ann Arbor, Michigan · NCT06839859

• Rapid-start HIV treatment to reduce stigma for people who inject drugs

  This project will test whether starting HIV treatment quickly (within 7 days) reduces stigma and improves care for people who inject drugs, including those in prison.

  Recruiting at 2 sites Yale University · Kajang and 2 other locations · NCT06541028

• Combination treatment for advanced pancreatic cancer

  This study is testing a new combination of treatments for people with advanced pancreatic cancer who haven't had treatment before to see if it helps manage their disease better.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06405490

• Low dead-space syringe and needle distribution for people who inject drugs in low- and middle-income countries

  This program will test whether offering low dead-space syringes and needles to people who inject drugs at needle and syringe programs in several low- and middle-income countries increases acceptability and use of safer injecting equipment.

  Recruiting at 9 sites Médecins du Monde · Yerevan and 8 other locations · NCT06395129

• Syringe-service telemedicine plus social-network HIV prevention program

  This program will test whether training people who inject drugs to recruit and educate their peers through syringe service telemedicine and social networks increases HIV testing and use of prevention and treatment services in Maryland.

  Recruiting Johns Hopkins University · Baltimore, Maryland and 1 other locations · NCT06103370

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.